DE602005025751D1 - Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle - Google Patents
Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelleInfo
- Publication number
- DE602005025751D1 DE602005025751D1 DE602005025751T DE602005025751T DE602005025751D1 DE 602005025751 D1 DE602005025751 D1 DE 602005025751D1 DE 602005025751 T DE602005025751 T DE 602005025751T DE 602005025751 T DE602005025751 T DE 602005025751T DE 602005025751 D1 DE602005025751 D1 DE 602005025751D1
- Authority
- DE
- Germany
- Prior art keywords
- target cell
- compositions
- hcv virus
- virus segment
- reducing hcv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
- C12N15/1131—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/111—General methods applicable to biologically active non-coding nucleic acids
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/11—Antisense
- C12N2310/113—Antisense targeting other non-coding nucleic acids, e.g. antagomirs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
- C12N2310/141—MicroRNAs, miRNAs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
- C12N2320/31—Combination therapy
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/50—Methods for regulating/modulating their activity
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2330/00—Production
- C12N2330/10—Production naturally occurring
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
- C12N2770/00011—Details
- C12N2770/24011—Flaviviridae
- C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US56835804P | 2004-05-04 | 2004-05-04 | |
PCT/US2005/015264 WO2005107816A2 (en) | 2004-05-04 | 2005-05-03 | Methods and compositions for reducing viral genome amounts in a target cell |
Publications (1)
Publication Number | Publication Date |
---|---|
DE602005025751D1 true DE602005025751D1 (de) | 2011-02-17 |
Family
ID=35320743
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
DE602005025751T Active DE602005025751D1 (de) | 2004-05-04 | 2005-05-03 | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle |
Country Status (15)
Country | Link |
---|---|
US (6) | US7307067B2 (de) |
EP (3) | EP2500431A3 (de) |
JP (2) | JP4943322B2 (de) |
AT (1) | ATE494373T2 (de) |
AU (1) | AU2005240118C1 (de) |
CA (2) | CA2564503C (de) |
CY (1) | CY1111755T1 (de) |
DE (1) | DE602005025751D1 (de) |
DK (1) | DK1747023T4 (de) |
ES (1) | ES2361458T5 (de) |
IL (1) | IL178679B (de) |
PL (1) | PL1747023T5 (de) |
PT (1) | PT1747023E (de) |
SI (1) | SI1747023T1 (de) |
WO (1) | WO2005107816A2 (de) |
Families Citing this family (42)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
AU2004294567A1 (en) | 2003-11-26 | 2005-06-16 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
AU2005240118C1 (en) | 2004-05-04 | 2014-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for reducing viral genome amounts in a target cell |
EP2471924A1 (de) | 2004-05-28 | 2012-07-04 | Asuragen, INC. | Verfahren und Zusammensetzungen mit microRNA |
EP2302055B1 (de) | 2004-11-12 | 2014-08-27 | Asuragen, Inc. | Verfahren und Zusammensetzungen, die miRNAs und miRNAa-inhibitorischen Molekülen verbunden sind |
WO2006113431A2 (en) * | 2005-04-13 | 2006-10-26 | University Of Massachusetts | Dual functional oligonucleotides for use as anti-viral agents |
CA2618995A1 (en) | 2005-08-10 | 2007-02-22 | The Rockefeller University | Antagomirs for use in inhibiting mir-122 |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
ATE494372T1 (de) | 2005-08-29 | 2011-01-15 | Regulus Therapeutics Inc | Verfahren für mir-122a-modulation |
US7516342B2 (en) | 2005-12-30 | 2009-04-07 | Intel Corporation | Method, apparatus and system to dynamically choose an optimum power state |
EP3431602A1 (de) * | 2006-04-03 | 2019-01-23 | Roche Innovation Center Copenhagen A/S | Pharmazeutische zusammensetzung mit anti-mirna-antisense-oligonukleotiden |
JP5814505B2 (ja) | 2006-04-03 | 2015-11-17 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物 |
CA2663878A1 (en) * | 2006-09-19 | 2008-03-27 | Asuragen, Inc. | Mir-200 regulated genes and pathways as targets for therapeutic intervention |
DK2149605T3 (da) | 2007-03-22 | 2013-09-30 | Santaris Pharma As | Korte RNA antagonist forbindelser til modulering af det ønskede mRNA |
AU2008228243B2 (en) | 2007-03-22 | 2014-05-15 | Santaris Pharma A/S | RNA antagonist compounds for the inhibition of Apo-B100 expression |
JP5149528B2 (ja) * | 2007-03-30 | 2013-02-20 | 学校法人東京医科大学 | C型肝炎ウイルスの複製を制御するマイクロrna |
WO2009029681A2 (en) * | 2007-08-27 | 2009-03-05 | The Regents Of The University Of California | Micrornas for inhibiting viral replication |
EP2198050A1 (de) | 2007-09-14 | 2010-06-23 | Asuragen, INC. | Mikrornas mit unterschiedlicher expression bei zervikalkarzinom und verwendungen davon |
AU2008306327B2 (en) * | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
WO2009070805A2 (en) | 2007-12-01 | 2009-06-04 | Asuragen, Inc. | Mir-124 regulated genes and pathways as targets for therapeutic intervention |
US8404659B2 (en) * | 2008-03-07 | 2013-03-26 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of MicroRNA related diseases |
US8258111B2 (en) | 2008-05-08 | 2012-09-04 | The Johns Hopkins University | Compositions and methods related to miRNA modulation of neovascularization or angiogenesis |
ES2541442T3 (es) | 2008-08-01 | 2015-07-20 | Roche Innovation Center Copenhagen A/S | Modulación mediada por microARN de factores estimulantes de colonias |
EP3067359A1 (de) | 2008-09-23 | 2016-09-14 | Scott G. Petersen | Selbstfreisetzende biolabile phosphatgeschützte pro-oligos für therapeutika auf oligonukleotidbasis und vermittlung von rna-interferenz |
EP2191834A1 (de) * | 2008-11-26 | 2010-06-02 | Centre National De La Recherche Scientifique (Cnrs) | Zusammensetzungen und Verfahren zur Behandlung von Retrovireninfektionen |
WO2010122538A1 (en) * | 2009-04-24 | 2010-10-28 | Santaris Pharma A/S | Pharmaceutical compositions for treatment of hcv patients that are non-responders to interferon |
US8563528B2 (en) | 2009-07-21 | 2013-10-22 | Santaris Pharma A/S | Antisense oligomers targeting PCSK9 |
DK2558578T3 (en) | 2010-04-13 | 2016-01-25 | Life Technologies Corp | CONFIGURATIONS AND METHODS FOR INHIBITION OF nucleic acid function |
SI2561078T1 (sl) | 2010-04-23 | 2019-01-31 | Cold Spring Harbor Laboratory | Nove strukturno oblikovane shRNA |
US9045749B2 (en) | 2011-01-14 | 2015-06-02 | The General Hospital Corporation | Methods targeting miR-128 for regulating cholesterol/lipid metabolism |
WO2013040251A2 (en) | 2011-09-13 | 2013-03-21 | Asurgen, Inc. | Methods and compositions involving mir-135b for distinguishing pancreatic cancer from benign pancreatic disease |
US8466159B2 (en) | 2011-10-21 | 2013-06-18 | Abbvie Inc. | Methods for treating HCV |
GB2515941A (en) | 2011-10-21 | 2015-01-07 | Abbvie Inc | Methods for treating HCV comprising at least two direct acting antiviral agent, ribavirin but not interferon |
EA201490836A1 (ru) | 2011-10-21 | 2014-11-28 | Эббви Инк. | Комбинационное лечение (например, с abt-072 или abt-333) с помощью daa для применения при лечении hcv |
US8492386B2 (en) | 2011-10-21 | 2013-07-23 | Abbvie Inc. | Methods for treating HCV |
JP2016518842A (ja) | 2013-05-01 | 2016-06-30 | レグルス セラピューティクス インコーポレイテッド | マイクロRNA化合物およびmiR−122をモジュレートする方法 |
CN112263682A (zh) | 2013-06-27 | 2021-01-26 | 罗氏创新中心哥本哈根有限公司 | 靶向pcsk9的反义寡聚体和缀合物 |
WO2016049512A1 (en) | 2014-09-26 | 2016-03-31 | University Of Massachusetts | Rna-modulating agents |
EP3218486A1 (de) | 2014-11-10 | 2017-09-20 | Glaxosmithkline Intellectual Property (No. 2) Limited | Langzeitwirkende kombinationszusammensetzungen und verfahren für hepatitis c |
CA2967195A1 (en) | 2014-11-10 | 2016-05-19 | Glaxosmithkline Intellectual Property (No.2) Limited | Long acting pharmaceutical compositions for hepatitis c |
CN109689063A (zh) | 2016-04-28 | 2019-04-26 | 埃默里大学 | 含有炔烃的核苷酸和核苷治疗组合物及其相关用途 |
CN111904973B (zh) * | 2020-07-27 | 2021-12-03 | 中国农业科学院兰州兽医研究所 | ssc-miR-122在制备调节猪繁殖与呼吸综合征病毒复制的药物中的应用 |
Family Cites Families (27)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
WO1990011092A1 (en) | 1989-03-21 | 1990-10-04 | Vical, Inc. | Expression of exogenous polynucleotide sequences in a vertebrate |
US5610050A (en) * | 1990-04-20 | 1997-03-11 | The General Hospital Corporation | Methods of preventing viral replication |
JPH06311885A (ja) † | 1992-08-25 | 1994-11-08 | Mitsubishi Kasei Corp | C型肝炎ウイルス遺伝子に相補的なアンチセンス化合物 |
US6423489B1 (en) † | 1992-09-10 | 2002-07-23 | Isis Pharmaceuticals, Inc. | Compositions and methods for treatment of Hepatitis C virus-associated diseases |
US5985847A (en) | 1993-08-26 | 1999-11-16 | The Regents Of The University Of California | Devices for administration of naked polynucleotides which encode biologically active peptides |
JPH10503364A (ja) † | 1994-05-10 | 1998-03-31 | ザ ジェネラル ホスピタル コーポレーション | C型肝炎ウイルスのアンチセンス阻害 |
US5922687A (en) | 1995-05-04 | 1999-07-13 | Board Of Trustees Of The Leland Stanford Junior University | Intracellular delivery of nucleic acids using pressure |
DE69725704T2 (de) | 1996-08-09 | 2004-05-13 | Alcon Manufacturing Ltd., Fort Worth | Konservierungssysteme fur cyclodextrine enthaltende arzneimittel |
US6824768B2 (en) * | 1998-12-18 | 2004-11-30 | Schering Corporation | Ribavirin-pegylated interferon alfa induction HCV combination therapy |
CA2442092A1 (en) | 2001-03-26 | 2002-10-17 | Ribozyme Pharmaceuticals, Inc. | Oligonucleotide mediated inhibition of hepatitis b virus and hepatitis c virus replication |
EP2386637B1 (de) * | 2001-09-28 | 2018-05-16 | Max-Planck-Gesellschaft zur Förderung der Wissenschaften e.V. | Mikrorna-moleküle |
FR2830254B1 (fr) * | 2001-09-28 | 2004-09-17 | Synkem | Nouvelles diphosphines, leurs complexes avec des metaux de transition et leur utilisation en synthese asymetrique |
EP1430157B1 (de) | 2002-02-20 | 2011-08-10 | Sirna Therapeutics, Inc. | Durch eine störung der rna vermittelte inhibierung der genexpression des hepatitis c virus (hcv) mit kurzer, störender nukleinsäure (short interfering nucleic acid, sina) |
US20040175732A1 (en) * | 2002-11-15 | 2004-09-09 | Rana Tariq M. | Identification of micrornas and their targets |
JP2006519008A (ja) * | 2003-02-10 | 2006-08-24 | 独立行政法人産業技術総合研究所 | 哺乳動物細胞の調節 |
JP2006517960A (ja) * | 2003-02-18 | 2006-08-03 | ファイザー インコーポレイテッド | C型肝炎ウイルスの阻害剤、それを使用する組成物および治療法 |
CA2533701A1 (en) | 2003-07-31 | 2005-02-17 | Isis Pharmaceuticals, Inc. | Oligomeric compounds and compositions for use in modulation of small non-coding rnas |
WO2005013904A2 (en) | 2003-08-04 | 2005-02-17 | University Of Massachusetts | Sars nucleic acids, proteins, vaccines, and uses thereof |
AU2004263124B2 (en) | 2003-08-07 | 2009-01-15 | Avi Biopharma, Inc. | Sense antiviral compound and method for treating ssRNA viral infection |
AU2004294567A1 (en) * | 2003-11-26 | 2005-06-16 | University Of Massachusetts | Sequence-specific inhibition of small RNA function |
AU2005240118C1 (en) * | 2004-05-04 | 2014-02-13 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and compositions for reducing viral genome amounts in a target cell |
US20070213292A1 (en) | 2005-08-10 | 2007-09-13 | The Rockefeller University | Chemically modified oligonucleotides for use in modulating micro RNA and uses thereof |
US20090203893A1 (en) | 2005-08-29 | 2009-08-13 | Regulus Therapeutics, Llc | Antisense compounds having enhanced anti-microrna activity |
JP5814505B2 (ja) | 2006-04-03 | 2015-11-17 | ロシュ・イノベーション・センター・コペンハーゲン・アクティーゼルスカブRoche Innovation Center Copenhagen A/S | antimiRNAアンチセンスオリゴヌクレオチドを含む医薬組成物 |
AU2008306327B2 (en) | 2007-10-04 | 2014-05-15 | Roche Innovation Center Copenhagen A/S | Micromirs |
WO2011000092A1 (en) | 2009-06-29 | 2011-01-06 | Matthew Hunsberger | A disc brake for a tape measure |
-
2005
- 2005-05-03 AU AU2005240118A patent/AU2005240118C1/en not_active Ceased
- 2005-05-03 EP EP12163232.7A patent/EP2500431A3/de not_active Withdrawn
- 2005-05-03 SI SI200531259T patent/SI1747023T1/sl unknown
- 2005-05-03 CA CA2564503A patent/CA2564503C/en not_active Expired - Fee Related
- 2005-05-03 JP JP2007511489A patent/JP4943322B2/ja not_active Expired - Fee Related
- 2005-05-03 PL PL05749437T patent/PL1747023T5/pl unknown
- 2005-05-03 DK DK05749437.9T patent/DK1747023T4/en active
- 2005-05-03 WO PCT/US2005/015264 patent/WO2005107816A2/en not_active Application Discontinuation
- 2005-05-03 PT PT05749437T patent/PT1747023E/pt unknown
- 2005-05-03 AT AT05749437T patent/ATE494373T2/de active
- 2005-05-03 US US11/122,328 patent/US7307067B2/en not_active Expired - Fee Related
- 2005-05-03 EP EP05749437.9A patent/EP1747023B2/de not_active Not-in-force
- 2005-05-03 EP EP10196635.6A patent/EP2338996A3/de not_active Withdrawn
- 2005-05-03 ES ES05749437.9T patent/ES2361458T5/es active Active
- 2005-05-03 DE DE602005025751T patent/DE602005025751D1/de active Active
- 2005-05-03 CA CA2912903A patent/CA2912903A1/en not_active Abandoned
-
2006
- 2006-10-17 IL IL178679A patent/IL178679B/en not_active IP Right Cessation
-
2007
- 2007-12-10 US US11/953,705 patent/US7838504B2/en not_active Expired - Fee Related
-
2010
- 2010-11-19 US US12/950,672 patent/US8217020B2/en not_active Expired - Fee Related
-
2011
- 2011-04-04 CY CY20111100346T patent/CY1111755T1/el unknown
- 2011-12-26 JP JP2011282593A patent/JP5602123B2/ja not_active Expired - Fee Related
-
2012
- 2012-06-21 US US13/529,694 patent/US8759312B2/en not_active Expired - Fee Related
-
2014
- 2014-05-16 US US14/280,156 patent/US9416362B2/en not_active Expired - Fee Related
-
2016
- 2016-08-12 US US15/235,946 patent/US20160348116A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
DE602005025751D1 (de) | Verfahren und zusammensetzungen zur verringerung von hcv virusgenommengen in einer zielzelle | |
WO2008033466A3 (en) | Compositions and methods for treatment of viral diseases | |
WO2011123645A3 (en) | Nucleoside phosphoramidates | |
WO2005123087A3 (en) | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase | |
EP2609923A3 (de) | Nukleosid-Phosphoramidate | |
WO2007095269A3 (en) | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection | |
EA200900297A1 (ru) | Ингибиторы вируса гепатита с | |
WO2008085508A3 (en) | Nucleoside aryl phosphoramidates for the treatment of rna-dependent rna viral infection | |
EA200700243A1 (ru) | Способы лечения гепатита с | |
MY176918A (en) | N- [ (2 ' r) -2' -deoxy-2' -fluoro-2' -methyl-p-phenyl-5' -uridylyl] - l-alanine 1-methylethyl ester and process for its production | |
BRPI0515596A (pt) | composição farmacêutica usada para o tratamento e/ou prevenção de hcv, e, métodos de inibir rna polimerase ns5b de hepatite c de tratar ou prevenir infecção por hepatite c em um mamìfero | |
EA201201356A1 (ru) | Композиция для лечения респираторных синцитиальных вирусов | |
EA200970358A1 (ru) | Нуклеозидный ингибитор для вгс(hcv) | |
EA200900154A1 (ru) | Фосфинатные соединения (варианты), фармацевтическая композиция на их основе, способ лечения вирусного гепатита с с ее помощью, терапевтическое средство на их основе и названные соединения для изготовления лекарства от вирусного гепатита с | |
WO2007084435A3 (en) | Methods for treating hepatitis c | |
EP2399575A3 (de) | Verfahren, Verwendungen und Zusammensetzungen zur Behandlung einer Infektion durch einen Virus aus der Familie der Flaviviridae durch Hemmung des Farnesoid X-Rezeptors (FXR) | |
ATE522532T1 (de) | Verbindungen zur behandlung von hepatitis c | |
ATE551343T1 (de) | Tetracyclische verbindungen zur behandlung von hepatitis c | |
DE602008004317D1 (de) | Verbindungen zur behandlung von hepatitis c | |
WO2010047830A3 (en) | Agents for hcv treatment | |
WO2010055164A3 (en) | Isoquinolone derivatives as inhibitors of plavivirus replication | |
ATE505473T1 (de) | Cyclopropylkondensierte indolobenzazepinderivate zur behandlung von hepatitis c | |
DE112004000961D2 (de) | Verwendung von Wirksubstanzen zur Vorbeugung oder Behandlung von Viruserkrankungen sowie Testsystem zum Auffinden solcher Wirksubstanzen | |
WO2006085979A3 (en) | Soluble forms of hendra and nipah virus g glycoprotein | |
DE602004031435D1 (de) | Cycloalkyl-heterozyklen zur behandlung des hepatitis-c-virus |